ArticleActa oncologica (Stockholm, Sweden)2025
Dosimetric impact of esophageal motion in esophagus-sparing radiotherapy of spinal metastases.
Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05109819 (ESO-SPARE), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ESO-SPARE: Esophagus Sparring Radiotherapy for Thoracic and Cervical Metastatic Spinal Cord Compression. A Randomized Phase III Study.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThe phase III trial (NCT05109819) investigates whether esophagus-sparing radiotherapy (RT) reduces dysphagia in patients with spinal metastases. This retrospective simulation study evaluates the dosimetric impact of inter-fractional esophageal motion in this setting. Patient/materials and methods: Patients receiving daily image-guided RT on high-quality cone beam computed tomography (CBCT)-equipped units between September 2023 and December 2024 were screened. Inclusion required five consecutive CBCTs with vertebrae T1-T10 in view and a visible esophagus. The esophagus was contoured on the planning CT (pCT) and five CBCTs. Standard and esophagus-sparing 25 Gy/5 fraction volumetric-modulated arc therapy plans were simulated for five thoracic targets. In esophagus-sparing plans, the esophageal D0.027cc was limited to 8 Gy equivalent dose in 2 Gy fractions (α/β = 3 Gy), consistent with the ESO-SPARE constraint. CBCT-based esophagus contours were rigidly transferred to the pCT after bony matching. Esophageal metrics (Mean, D0.027cc-D5cc, V8.5 Gy) were extracted from the original plan and compared across CBCT and pCT contours and between plan types. Inter-fraction motion was assessed using 95% Hausdorff Distance (HD). CBCT quality was evaluated in two patients (five targets) using Dice similarity coefficients and interobserver 95% HDs.
resultsTwelve patients with 23 targets were simulated. Inter-fraction motion led to dose constraint violations in 20 of 23 plans, though only small esophageal volumes entered the high-dose region. Dice scores > 0.8 confirmed good esophageal visibility on CBCT. Most 95% HDs fell within interobserver variability, indicating motion was comparable to contouring uncertainty.
interpretationDespite constraint violations, high-dose exposure was limited to small esophageal volumes, and overall sparing was preserved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.